Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial

BACKGROUND: Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk for disease progression. METHODS: This was an open-label, sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Moya, Jaynier, Temech, Marisol, Parra, Sergio, Juarez, Erick, Hernandez-Loy, Reinaldo, Gutierrez, Juan C Moises, Diaz, Jorge, Hussain, Rubaba, Segal, Scott, Xu, Claire, Skingsley, Andrew, Schnell, Gretja, El-Zailik, Asma, Sager, Jennifer E, Aldinger, Melissa, Alexander, Elizabeth L, Acloque, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372714/
https://www.ncbi.nlm.nih.gov/pubmed/37520411
http://dx.doi.org/10.1093/ofid/ofad344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372714/
https://www.ncbi.nlm.nih.gov/pubmed/37520411
http://dx.doi.org/10.1093/ofid/ofad344

Ejemplares similares